Long COVID linked to dopamine nerve loss in the brain

A new eBioMedicine study finds long COVID patients show an average 18% reduction in dopamine-releasing nerve terminals in the striatum, measured by VMAT2 binding, with lower dopamine cell density correlating with apathy, slower motor speed, and memory issues; blood biomarkers did not reflect these brain changes. The authors suggest dopamine-enhancing treatments could help some patients, but note the study’s small, associative design and call for larger, longitudinal research to confirm causality and guide therapy.